Risk Prediction for Adverse Events during Initiation of @entity2778 and XXXX for the Treatment of @entity955 .

@entity1 @entity2781 @entity1165 @entity1166 @entity2778 @entity955 @entity1162 @entity67 @entity943 @entity1168
BACKGROUND: Inpatient antiarrhythmic drug initiation for @entity955 is mandated for @entity2781 (DF) and is often performed for @entity2778 (SL), particularly if proarrhythmia risk factors are present. Whether low-risk @entity1 can be identified to safely allow outpatient initiation is unknown. METHODS: A single-center retrospective cohort study was performed on @entity1 initiated with DF or SL. Risk factors for adverse events (AEs), defined as any @entity943 or electrocardiogram change requiring dose reduction or cessation, were identified. RESULTS: Of 329 @entity1 , 227 (69%) received SL and 102 (31%) DF. The cohort had a mean age of 63      13 years; 70% of @entity1 were male and had a baseline QTc of 440      37 ms. A total of 105 AEs occurred in 92 @entity1 : @entity1162 or @entity1165 in 70 @entity1 (67% of AEs), @entity1168 in 35 @entity1 (33% of AEs), with some experiencing both AE types. @entity943 were seen in 23 @entity1 (7%) and @entity1166 in one (0.3%). Total AE rates were similar between drugs (P = 0.09); however, DF @entity1 had more @entity1162 or @entity943 (P = 0.001). In SL @entity1 , there were no predictors for @entity1162 or @entity67 . In DF @entity1 , higher baseline QTc interval (odds ratio = 1.64/25 ms, P = 0.01) was an independent predictor of @entity1162 . For @entity1 without proarrhythmia risk factors, overall AE rate was 26%. CONCLUSIONS: In conclusion, AEs are common during DF and SL initiation but rarely severe in hospitalized inpatients. Baseline QTc predicts AEs for DF @entity1 only and AE are common even in "low-risk" @entity1 . These results support in-hospital drug initiation for all DF and SL @entity1 .
